Anti-HER2 small molecule imaging agent - Affibody

Drug Profile

Anti-HER2 small molecule imaging agent - Affibody

Alternative Names: [111In]ABY-025; [68Ga]ABY-025; ABY-002; ABY-025; ABY0125; Anti-HER2 Affibody

Latest Information Update: 04 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Affibody; GE Healthcare
  • Developer Affibody; Biomedical Radiation Sciences; Herlev Hospital; Swedish Cancer Society
  • Class Peptide fragments; Radiopharmaceuticals; Small molecules
  • Mechanism of Action Diagnostic imaging enhancers; Single-photon emission-computed tomography enhancers
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I/II Breast cancer

Most Recent Events

  • 04 Nov 2017 No recent reports of development identified for phase-I development in Breast-cancer(Diagnosis) in Denmark (IV, Injection)
  • 21 Sep 2015 Early clinical development for Breast cancer (Diagnosis) is ongoing in Sweden and Denmark
  • 09 Dec 2011 Adverse events and pharmacokinetics data from a phase I/II trial in Breast cancer diagnosis presented at the 34th San Antonio Breast Cancer Symposium (SABCS-2011)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top